<DOC>
	<DOCNO>NCT01748500</DOCNO>
	<brief_summary>The main objective trial : 1 . To assess activity safety pantoprazole docetaxel ( prednisone ) men metastatic CRPC receive prior chemotherapy . 2 . To evaluate archival prostate cancer tissue men include clinical trial evidence autophagy use IHC LC3B , ATG5 , p62 well ERG . 3 . To evaluate pharmacokinetic interaction pantoprazole docetaxel .</brief_summary>
	<brief_title>Pantoprazole Docetaxel Men With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Age ≥18yrs ECOG performance status ≤2 Histologically cytologically confirm adenocarcinoma prostate Clinical radiological evidence metastatic disease Disease progression receive androgen deprivation therapy increase PSA 25 % great nadir value measure 3 consecutive occasion least 1 week apart Antiandrogen therapy must stop least 4 week prior start trial treatment ( 6 week case bicalutamide nilutamide ) reduction serum PSA therapy initiate Baseline serum prostatespecific antigen ( PSA ) ≥10ng/ml Total testosterone &lt; 50 ng/dL ( &lt; 1.7 nmol/L ) Adequate hematologic value : neutrophil count ≥1,500/mm3 , platelet ≥100,000/mm3 , hemoglobin ≥10.0 g/dl Adequate hepatic renal function : total bilirubin level ≤1.5 x ULN ( unless secondary document Gilbert 's disease ) ; ALT , AST , creatinine ≤1.5 x ULN Ability understand sign consent study Prior treatment prostate cancer chemotherapy radioisotopes History another cancer within precede five year ( except basal squamouscell skin cancer adequately treat superficial bladder cancer ) Known suspect brain leptomeningeal metastases Symptomatic peripheral neuropathy grade 2 high Major surgery within 4 week start trial treatment Radiotherapy ≥25 % bone marrow radiotherapy within 4 week start trial treatment Known hypersensitivity trial treatment hypersensitivity component Any concomitant drug contraindicate use trial treatment Any serious underlying medical condition could impair ability patient participate trial Any psychological , familial , sociological patient relate factor might preclude compliance study protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>metastatic</keyword>
</DOC>